For investors in Clovis Oncology (CLVS), this may be a case of “Better late, than never.”
Two years after an R&D expert publicly questioned the veracity of clinical trial data released by the drug maker, Clovis executives disclosed that the Securities and Exchange Commission may pursue a civil enforcement action or administrative proceeding against the company.
About the Author Reprints
